Inactive Instrument
EntreMed Inc Stock Nasdaq
Stocks
US29382F2020
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-13 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 2.26M 2.02M 1.88M 1.71M 3.22M 219M 3.25M 22.62M 8.85M 111M 8.49M 8.31M 358M | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 24.12M 21.53M 20.09M 18.25M 34.34M 2.34B 34.68M 241M 94.34M 1.19B 90.54M 88.58M 3.82B | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.46% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 2025-07-20 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 2025-05-15 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 2016-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 2013-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 2023-03-20 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 2023-03-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.61% | +1.72% | +38.30% | +106.93% | 1,043B | |
| -0.76% | -0.84% | +35.21% | +62.70% | 618B | |
| +0.39% | +4.81% | +17.81% | +83.77% | 481B | |
| -0.29% | -0.99% | +64.79% | +37.06% | 351B | |
| +1.47% | +3.30% | +21.63% | +42.36% | 338B | |
| +0.98% | +2.11% | +11.42% | +34.80% | 269B | |
| +1.60% | +1.82% | -6.60% | +11.33% | 244B | |
| -1.37% | +0.04% | +38.29% | +52.33% | 220B | |
| +0.17% | -0.27% | +24.40% | +96.82% | 182B | |
| Average | +0.21% | +0.28% | +27.25% | +58.68% | 416.3B | |
| Weighted average by Cap. | -0.10% | +0.60% | +30.61% | +69.18% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 28.54M 25.48M 23.77M 21.6M 40.64M 2.76B 41.03M 285M 112M 1.4B 107M 105M 4.52B | 20.71M 18.5M 17.25M 15.67M 29.49M 2.01B 29.78M 207M 81.03M 1.02B 77.77M 76.08M 3.28B |
| Net income | -39.26M -35.06M -32.7M -29.71M -55.9M -3.8B -56.45M -393M -154M -1.93B -147M -144M -6.21B | -48.06M -42.92M -40.04M -36.37M -68.44M -4.65B -69.1M -481M -188M -2.37B -180M -177M -7.61B |
| Net Debt | 6.05M 5.4M 5.04M 4.58M 8.62M 586M 8.7M 60.51M 23.67M 298M 22.72M 22.22M 958M | 21.85M 19.52M 18.21M 16.54M 31.12M 2.12B 31.42M 219M 85.49M 1.08B 82.05M 80.27M 3.46B |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
